Verge Genomics has announced the start of its Phase 1b trial for VRG50635, a potential treatment for amyotrophic lateral sclerosis (ALS), covering both sporadic and familial forms.
Constant Therapeutics LLC, specializing in biopharmaceuticals, announced the first patient dosed in their Phase 2 trial of TXA127, a peptide therapy aimed at improving post-stroke recovery.
Fate Therapeutics Reveals Commencement of Initial Human Trial for FT825 / ONO-8250 in Individuals Suffering from HER2-positive Progressive Solid Cancers.
Medison Pharma and Regeneron Ireland DAC have formed an exclusive partnership for Medison to distribute Regeneron's innovative treatment, Libtayo® (cemiplimab).
Lutikizumab Demonstrates Encouraging Outcomes in Phase 2 Study Among Individuals with Moderate to Advanced Hidradenitis Suppurativa, Progressing to Next Trial Stage.
The EU Commission has approved Eylea™ 8 mg, an 8 mg aflibercept (114.3 mg/ml) injectable, for treating neovascular age-related macular degeneration and diabetic macular edema-related vision loss.
Curevo Vaccine has reported its second-phase study for Amezosvatein, This advanced shingles immunization demonstrates effectiveness against Shingrix in direct comparison.